- Home
- ZYME vs NBR Comparison
ZYME vs NBR Comparison
Compare ZYME & NBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZYME | NBR |
|---|---|---|
| Founded | 2003 | 1952 |
| Country | United States | Bermuda |
| Employees | N/A | 13900 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZYME | NBR |
|---|---|---|
| Price | $23.10 | $79.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | $38.90 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 510.3K | 225.9K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $183.10 | $3.65 |
| Revenue Next Year | N/A | $4.88 |
| P/E Ratio | ★ N/A | $4.33 |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $11.86 | $30.90 |
| 52 Week High | $29.75 | $112.90 |
Technical Indicators
Market Signals| Indicator | ZYME | NBR |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 39.10 |
| Support Level | $22.20 | $75.45 |
| Resistance Level | $23.66 | $84.48 |
| Average True Range (ATR) | 0.86 | 3.45 |
| MACD | -0.27 | 0.54 |
| Stochastic Oscillator | 11.30 | 18.17 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.